NetJets Announces Collaboration With Acclaimed Artist Silvère Jarrosson
21.5.2024 16:10:00 EEST | Business Wire | Press release
For the 23rd consecutive year, NetJets, the global leader in private aviation, proudly announces its partnership with Art Basel. To highlight its commitment to the arts, NetJets will collaborate with French abstract artist Silvère Jarrosson to create a new art collection exclusively for NetJets that will be displayed at the Art Basel shows in Basel, Paris and Miami Beach.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521442854/en/
Silvère Jarrosson, credit Julien Benhamou
Born and raised in Paris, Jarrosson trained as a ballet dancer at the renowned Opera National de Paris at only 10 years old but transitioned into abstract painting a decade ago. His background in ballet is seen throughout his motion and fluidity while creating his works of art. Represented by contemporary art agency Studio Artera in Paris, Jarrosson is known for using his whole body to make his art – as he moves or ‘dances’ with the canvas to create his signature acrylic pieces.
At only 31 years of age, Jarrosson has received widespread praise and has had his work showcased globally. His art is featured in prestigious institutions such as the Villa Medici in Rome, the Unterlinden Museum in Colmar, the Lambert Collection in Avignon, the Crédit du Nord Collection, the Mobilier National and the Opera National de Paris, among others.
Jarrosson’s project created for NetJets, entitled “Inner Horizons”, offers Owners – the individuals and businesses who are clients of NetJets’ private jet ownership model – captivating insight into his world of poetic immersion, where his spectators become part of the creative inspiration for his shows and projects. His work will be featured in NetJets' exclusive area within the Collectors Lounge. Accessible only by Owners, it will offer a secluded space for guests to enjoy hospitality throughout the show week of Art Basel in Basel. The show aims to merge external travel experiences made possible by NetJets with inner travel experiences created by Jarrosson’s art.
Patrick Gallagher, President of Sales, Marketing & Service, commented: “We are delighted with this partnership. We admire the synergy from the movement Silvère uses to create his art pieces. His beautiful artwork truly moves observers who watch him paint. Despite coming from different industries, we align in our passion to both create and capture exceptional experiences for others. As many of our Owners are deeply interested in fine art, we believe this partnership will be both inspiring and exciting as Silvère’s career continues to flourish.”
Globally recognised for its revolutionary shared ownership business model, NetJets’ impeccable reputation spans more than 60 years and has reshaped how people fly private. NetJets proudly maintains and operates over 1,000 aircraft, grants access to more than 5,000 airports and employs over 8,300 private aviation professionals to deliver outstanding service.
About NetJets
Originally incorporated in 1964 as Executive Jet Airways, NetJets has been setting – and exceeding – industry standards for over 60 years. Today, NetJets is proud to be a Berkshire Hathaway company known for its unwavering commitment to safety and service. NetJets’ portfolio of distinctive companies, encompassing NetJets, Executive Jet Management, QS Partners and QS Security, offers a variety of customisable travel solutions, including shared ownership, lease and jet card options, aircraft management, private jet chartering, brokerage and acquisition services and specialised security services. This comprehensive suite of solutions is why so many of the world’s most discerning travellers choose NetJets generation after generation. It is also because NetJets has the largest, most diverse private jet fleet in the world, which grants anytime access to even the most remote destinations across the globe. To learn more about the leader in private aviation, visit netjets.com today.
About Studio Artera
Studio Artera is an art and talent agency based in Paris that supports the finest visual artists.
We represent artists and integrate art in all contexts by creating meaningful artistic collaborations with brands, companies, cultural institutions, and cities. Driven by the desire to reach an ever-wider audience through art, we build artistic narratives with our clients to inspire millions of people around the world.
Clients of Studio Artera include Louis Vuitton, Prada, Levi’s, Bombay Sapphire, the Hoxton Group, the City of Paris, Château Charmail, and Viva Technology.
To learn more about us, please visit www.studioartera.com
About Art Basel
Founded in 1970 by gallerists from Basel, Art Basel today stages the world’s premier art shows for Modern and contemporary art, sited in Basel, Miami Beach, Hong Kong, and Paris. Defined by its host city and region, each show is unique, which is reflected in its participating galleries, artworks presented, and the content of parallel programming produced in collaboration with local institutions for each edition. Art Basel’s engagement has expanded beyond art fairs through new digital platforms and initiatives such as the Art Basel and UBS Global Art Market Report. Art Basel’s Global Media Partner is The Financial Times. For further information, please visit artbasel.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521442854/en/
Contact information
Media Contact:
NetJets/NetJets Europe
pressnetjets@kwtglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
